MyFinsight
Home
Blog
About
Proceeds from maturities
of marketable...
$131,030K
(-43.60%↓ Y/Y)
Proceeds from exercise of
stock options and...
$1,918K
(-3.96%↓ Y/Y)
Net cash provided by
(used in) investing...
$32,860K
(-25.08%↓ Y/Y)
Net cash provided by
financing activities
$1,918K
(-91.21%↓ Y/Y)
Canceled cashflow
$98,170K
Net decrease in cash
and cash...
-$65,475K
(-50.43%↓ Y/Y)
Canceled cashflow
$34,778K
Stock-based compensation
$15,863K
(-7.86%↓ Y/Y)
Accrued and other
liabilities
$2,508K
(-24.44%↓ Y/Y)
Accounts payable
$664K
(-87.91%↓ Y/Y)
Accretion of loan exit fee
and amortization of...
$646K
Depreciation and
amortization
$132K
(-35.29%↓ Y/Y)
Reduction in the carrying
amount of operating...
$120K
(-86.68%↓ Y/Y)
Purchase of marketable
securities
$98,056K
(-47.63%↓ Y/Y)
Purchase of internal use
software license
$114K
Net cash used in
operating activities
-$100,253K
(8.20%↑ Y/Y)
Canceled cashflow
$19,933K
Net loss
-$109,473K
(14.62%↑ Y/Y)
Prepaid expense and
other current assets
$9,428K
(126.53%↑ Y/Y)
Accretion of discount and
amortization of premium on...
-$1,098K
Operating lease
liabilities
-$187K
(78.33%↑ Y/Y)
Back
Back
Cash Flow
Vera Therapeutics, Inc. (VERA)
Vera Therapeutics, Inc. (VERA)
source: myfinsight.com